Perrigo Migraine Analgesic, Antifungal Slated for Spring Launch
This article was originally published in The Tan Sheet
Executive Summary
Perrigo has become the first firm to receive FDA approval for both a generic migraine analgesic and a one-day vaginal antifungal treatment, the company announced Dec. 4
You may also be interested in...
Perrigo Riding High On Wall Street As ANDA Approvals Resume
Perrigo's resolution of quality control problems - and the ANDA approvals that have followed - are drawing Wall Street enthusiasm as the firm's stock price surged almost 69% in the second quarter.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands